This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 5mg | $50 | 3-6 Days |
| 10mg | $70 | 3-6 Days |
| 25mg | $100 | 3-6 Days |
| 50mg | $150 | 3-6 Days |
| 100mg | $250 | 3-6 Days |
| 250mg | $450 | 3-6 Days |
| 500mg | $750 | 3-6 Days |
: Cat #: V2838 CAS #: 1446712-19-1 Purity ≥ 98%
Description: SNG1153 is a synthetic ER-α36 modulator which shows promising activities in various in vitro and in vivo models. SNG-1153 is the 2nd generation small molecule for cancer therapy developed by Shenogen Pharma Group. SNG-1153 has inhibitory effects on TKI-resistant CML cells. SNG1153 shows significant inhibition at low micromolar concentrations in ER-α36 overexpressed cell lines including the one resistant to tamoxifen. SNG1153 exhibited a linear PK profile with a bioavailability of more than 55% in the rat PK study. In the in-vivo efficacy studies, 3 doses were investigated and SNG1153 showed dose-dependent inhibition. The tumor growth inhibition at high dose was 57% in the breast cancer Bcap-37 xenograft model, 65% in the endometrial cancer Ishikawa xenograft model and 52% in lung adenocarcinoma SPC-A-1 xenograft model.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 406.35 |
|---|---|
| Molecular Formula | C₂₁H₁₇F₃O₅ |
| CAS No. | 1446712-19-1 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: ≥ 32 mg/mL |
| Water: <1 mg/mL | |
| Ethanol: | |
| SMILES Code | FC(F)(F)C(C=C1)=CC=C1C2=C(O)C(C(C(O)=CC(O)=C3C/C=C(C)/C)=C3O2)=O |
| Synonyms | SNG1153; SNG-1153; SNG 1153 |
| Protocol | In Vitro | In vitro activity: SNG-1153 is the 2nd generation small molecule for cancer therapy from Shenogen Pharma Group. SNG-1153 has inhibitory effects on TKI-resistant CML cells. Kinase Assay: Cell Assay: SNG-1153 is the 2nd generation small molecule for cancer therapy from Shenogen Pharma Group. SNG-1153 has inhibitory effects on TKI-resistant CML cells. |
|---|---|---|
| In Vivo | SNG1153 shows significant inhibition at low micromolar concentrations in ER-α36 overexpressed cell lines including the one resistant to tamoxifen. SNG1153 exhibited a linear PK profile with a bioavailability of more than 55% in the rat PK study. In the in-vivo efficacy studies, 3 doses were investigated and SNG1153 showed dose-dependent inhibition. The tumor growth inhibition at high dose was 57% in the breast cancer Bcap-37 xenograft model, 65% in the endometrial cancer Ishikawa xenograft model and 52% in lung adenocarcinoma SPC-A-1 xenograft model |
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 2.4609 mL | 12.3047 mL | 24.6093 mL | 49.2187 mL |
| 5mM | 0.4922 mL | 2.4609 mL | 4.9219 mL | 9.8437 mL |
| 10mM | 0.2461 mL | 1.2305 mL | 2.4609 mL | 4.9219 mL |
| 20mM | 0.1230 mL | 0.6152 mL | 1.2305 mL | 2.4609 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.